HKSTP
Hong Kong Science and Technology Parks Corporation (HKSTP) today held its first-ever hybrid Elevator Pitch Competition (EPiC), with over 600 startups from Hong Kong and around the world joining the annual signature event. HKSTP is approaching 20 years of leading innovation in Hong Kong with the return of EPiC 2021 to its iconic home at sky100 at the top of the International Commerce Centre in West Kowloon to re-create a genuine 60-second elevator pitch experience.
In its sixth year, the annual EPiC event in hybrid format for the first time, allowed overseas innovators to go beyond geographical boundaries and join the virtual EPiC event and journey live. This year’s event surpassed all expectations, attracting over 600 entries from 40 countries and cities across five continents. A total of over 160 contestants entered the semi-final round, with nearly 60% from overseas.
This year’s overall EPiC Champion, Winner of Green Tech & Construction Tech Category, as well as the “My Favourite Pitcher” award belong to Hong Kong-based archiREEF. The Greentech startup beat all other finalists with its innovative climate solutions and eco-engineering technology for ocean ecosystems restoration. The company combines expertise in marine biology and the latest technologies in 3D printing techniques and material science to create artificial habitats that are best suited for different marine life anywhere in the world.
The other three tech category winners included: FinTech Winner, Hong Kong-based Wizpresso; Health Technology Winner, Hong Kong-based PointFit Technology, and Smart City Winner, Israel-based Intelligent Traffic Control (ITC). All EPiC entries this year were focused on one of four key themes: FinTech, Green Tech & Construction Tech, Health Technology, and Smart City.
Albert Wong, CEO at HKSTP, said: “The return of our flagship pitching and investment event EPiC 2021 at the iconic sky100 is the ideal platform to lead into our 20th year, while the record participation is a showcase of the city’s growing entrepreneurial strength and world-class I&T potential. The EPiC week of activities provides a unique borderless experience that educates and connects innovators around the world with insights to sharpen entrepreneurial skills and deepen knowledge on the thriving Hong Kong and Greater Bay Area market. EPiC is where we unlock opportunities, where innovation begins and where talent flourishes as pioneers and innovators connect in a genuine haven of global innovation and investment.”
EPiC is a week-long platform generating opportunities not only for the winners but for all participants. Global and local entrepreneurs have interacted with active investors and innovation ecosystem leaders at this year’s EPiC competition. Meanwhile, physical and virtual guests from various industries and territories explored a wealth of GBA and international business partnership, as well as investment opportunities. The competition leads on to the Investment & Business Matching from November 8-12 and finally the Investment Conference on November 12, to complete a week of immersion into HKSTP’s world-class I&T ecosystem.
Since its inception in 2016, HKSTP’s EPiC has drawn a huge number of international participants to grasp a one-minute elevator pitch opportunity to some of the most demanding investors and judges in Hong Kong. The top ten finalists were given another opportunity to face the judges in a three-minute live pitch and two-minute Q&A. The overall champion took away a cash prize of US$100,000, while each of the category winners received a cash prize of US$10,000 and all ten finalists won US$6,000 each.
List of Winners:
Award |
Company |
Market |
Overall Champion and Green Tech & Construction Tech Category Winner |
archiREEF |
Hong Kong |
FinTech Category Winner |
Wizpresso |
Hong Kong |
Health Technology Category Winner |
PointFit Technology |
Hong Kong |
Smart City Category Winner |
Intelligent Traffic Control (ITC) |
Israel |
My Favourite Pitcher |
archiREEF |
Hong Kong |
Other Top 10 Finalists: |
Aortyx |
Spain |
|
Clear Robotics |
Hong Kong |
|
Novai |
UK |
|
Papkot |
France |
|
TicTAP – Simply Connect |
Spain |
|
Vista InnoTech |
Hong Kong |
About Hong Kong Science and Technology Parks Corporation
Hong Kong Science and Technology Parks Corporation (HKSTP) has for 20 continuous years committed to building up Hong Kong as an international innovation and technology hub to propel success for local and global pioneers today and tomorrow. HKSTP has established a thriving I&T ecosystem that is home to three unicorns and Hong Kong’s leading R&D hub with over 11,000 research professionals and over 1,000 technology companies focused on healthtech, AI and robotics, fintech and smart city technologies.
Established in 2001, we attract and nurture talent, accelerate and commercialise innovation and technology for entrepreneurs on their journey of growth in Hong Kong, to the Greater Bay Area, Asia and beyond. Our growing innovation ecosystem is built around our key locations of the Hong Kong Science Park in Shatin, InnoCentre in Kowloon Tong and three modern InnoParks in Tai Po, Tseung Kwan O and Yuen Long. The three InnoParks are realizing a vision of re-industrialisation for Hong Kong. The goal is sectors like advanced manufacturing, electronics and biotechnology are being reimagined for a new generation of industry.
Through our infrastructure, services, expertise and network of partnerships, HKSTP will help establish innovation and technology as a pillar of growth for Hong Kong, while reinforcing Hong Kong’s international I&T hub status as a launchpad for global growth at the heart of the GBA innovation powerhouse.
More information about HKSTP is available at www.hkstp.org
View source version on businesswire.com: https://www.businesswire.com/news/home/20211105005610/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Sonrotoclax Data at ASH 2025 Confirm Foundational Potential Across B-cell Malignancies8.12.2025 00:00:00 CET | Press release
Novel BCL2 inhibitor sonrotoclax monotherapy demonstrates deep and durable clinical responses in R/R MCL and R/R CLLSonrotoclax in combination with BRUKINSA demonstrated rapid MRD negativity in treatment-naive CLL, regardless of high-risk features BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data on sonrotoclax, a next-generation investigational BCL2 inhibitor, demonstrating meaningful clinical benefit as monotherapy and in combination across B-cell malignancies. These data were featured at the 67th American Society of Hematology (ASH) Annual Meeting & Exposition in Orlando, Florida. The five presentations highlight durable responses in heavily pretreated patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL) and additional studies showing deep, rapid, and sustained undetectable minimal residual disease (uMRD) rates with sonrotoclax-based combinations in patients with treatment-naive chronic lymphocytic leukemi
Andersen Consulting tilføjer samarbejdsfirmaet Codezilla7.12.2025 21:19:00 CET | Pressemeddelelse
Andersen Consulting styrker sine kompetencer inden for digital transformation gennem en samarbejdsaftale med Codezilla, et firma med hovedsæde i Rumænien, der udvikler specialtilpasset software. Codezilla specialiserer sig i at udvikle skræddersyede softwareprodukter, der løser forretningsmæssige udfordringer gennem en tværfaglig tilgang, som kombinerer softwareudvikling med dybdegående marketingekspertise. Med over 30 år på markedet fungerer firmaet som implementerings- og digital konsulentressource for reklamebureauer, samtidig med at de arbejder med en bred kundebase, herunder virksomheder inden for sundhedssektoren og medicinsk udstyr. Codezillas interne teams strækker sig over teknik, design og strategi og leverer omnichannel-løsninger til både regionale og globale kunder. "Vi tror på, at fantastisk software er resultatet af solid ingeniørkunst og disciplineret eksekvering," udtaler Sebastian Doroftei, administrerende direktør for Codezilla. "Vores samarbejde med Andersen Consulti
Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 17:00:00 CET | Press release
AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th
CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 13:00:00 CET | Press release
Summit debuts Mayors in Motion initiative and CoMotion Urban Visionary Distinction as Riyadh showcases its rise as global mobility testbed Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom